As I began my journey in the dual-degree MBA and Master’s in Asset Management program at SOM, I was excited about blending advanced business skills with in-depth asset management knowledge. My goal was clear: use both my qualitative and quantitative abilities to invest for a mission-driven organization. After graduating, I joined the University of Chicago’s investment office, where I help manage the university’s venture capital portfolio. Working in the endowment sector is incredibly fulfilling. When we do our job right, we have a direct role in supporting financial aid and advancing world-class research. Every investment decision I make is a step toward enhancing the university’s mission.
One of the standout experiences in the Asset Management program was the Investing Excellence course led by Dean Takahashi and Jim Millar. It offered us direct insights from some of the best active managers in the field. What I learned is profound: it’s very tough to consistently outperform the market. Success in active management demands an edge, unwavering honesty, and the courage to make bold choices. This lesson remains crucial, especially as our markets evolve. During my time in the program, the launch of AI models like GPT-3.5 highlighted how rapidly technology is changing. Even with the growing wealth of available information, market success still favors those who can discern the most relevant opportunities and know when to act. It’s not about choosing between AI and human judgment; it’s about leveraging both for the best outcomes.
I’ve also experienced unexpected perks from my SOM education. The network in the endowment and foundation space is robust, with many connections to SOM and Yale. I’m grateful to be among accomplished Chief Investment Officers (CIOs) and investors who continually inspire me. It’s motivating to see my classmates engaging in impactful work across various sectors, including climate tech, healthcare, and education.
My passion lies in supporting innovative investors who see potential in founders developing pioneering technologies. I’m particularly enthusiastic about the possibilities AI holds for healthcare and biotech. Investing in people who are creating technologies that can lead to groundbreaking treatments and enhance the quality of life feels truly rewarding.
According to recent statistics from a 2023 Deloitte survey, more than 80% of healthcare executives view AI as a game-changer for the industry. This highlights the exciting role AI will play not just now, but in the future of healthcare. As I support investments in transformative technologies, I’m optimistic about what lies ahead.—in both our economy and society as a whole.
